BlackRock Inc. bought a new position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) in the second quar

Bank of America Corp DE boosted its holdings in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON)

Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) duri

Jim Cramer likes Babcock & Wilcox and Smithfield Foods. He also advises taking some profits on B

DEER PARK, Ill., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company

The Fear & Greed Index, which measures market sentiment, declined while remaining in the Greed z

Canaccord Genuity analyst Gary Nachman maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy an

Eton Pharmaceuticals beat on both top and bottom lines last night. Management is licensing a new dru

Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular

Dow falls 0.26% while Nasdaq drops 0.51%. Energy shares rise 1.3%, tech stocks fall 0.6%. US retail

B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a

Eton Pharmaceuticals, Inc. delivered record Q2 2026 results, with product sales up 99% and full-year

U.S. stocks up, Dow Jones 0.1% higher. HeartFlow (HTFL) shares rise 26.5% on better-than-expected ea

Gainers Capricor Therapeutics (NASDAQ:CAPR) stock rose 94.8% to $8.2 during Friday's pre-market

Top analysts changed outlook on top names. Mizuho raised price target for AIT from $355 to $400. See

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETO

Eton Pharmaceuticals Inc (NASDAQ: ETON) rose in pre-market trading after reporting strong Q2 results

Eton Pharmaceuticals, Inc. (ETON) Q2 2026 Earnings Call Transcript

Eton Pharmaceuticals NASDAQ: ETON reported second-quarter revenue nearly doubled from a year earlier

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.35 per share, beating the Z

Eton Pharmaceuticals (NASDAQ:ETON) reported second-quarter financial results on Thursday. The transc

Gainers Akanda (NASDAQ:AKAN) stock rose 109.4% to $10.49 during Thursday's after-market session

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.43 per share which beat the ana

DEER PARK, Ill., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETO

Bank of New York Mellon Corp cut its position in Eton Pharmaceuticals, Inc. (NASDAQ: ETON) by 12.9%

ASN-001 targets the substantially larger population of moderate infantile hemangiomas currently trea

DEER PARK, Ill., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company

DEER PARK, Ill., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company

New formulation of KHINDIVI (hydrocortisone) oral solution successfully showed bioequivalence to ALK

DEER PARK, Ill., July 29, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy

Eton Pharmaceuticals (ETON) was a big mover last session on higher-than-average trading volume. The

Canaccord Genuity analyst Gary Nachman initiates coverage on Eton Pharmaceuticals (NASDAQ:ETON) w

On May 29, 2026, Eton Pharmaceuticals Inc (ETON) shares fell 4.3% today, bringing the current price

IMPAVIDO® is the first and only FDA-approved oral therapy for visceral, cutaneous, and mucosal leish

DEER PARK, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETO

Eton Pharmaceuticals, Inc. (ETON) Q1 2026 Earnings Call Transcript

Eton Pharmaceuticals NASDAQ: ETON raised its 2026 revenue outlook after reporting record first-quart

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Z

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.14 per share which beat the ana

Q1 2026 product sales of $24.3 million, representing 73% growth over Q1 2025 Raising full year reven

Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pha

B. Riley Securities analyst Madison El-Saadi maintains Eton Pharmaceuticals (NASDAQ:ETON) with a

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETO

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy